Vasculitis Treatment

Vasculitis Treatment

Global Vasculitis Treatment Market to Reach US$734.0 Million by 2030

The global market for Vasculitis Treatment estimated at US$542.4 Million in the year 2023, is expected to reach US$734.0 Million by 2030, growing at a CAGR of 4.4% over the analysis period 2023-2030. Immunosuppressants, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$153.8 Million by the end of the analysis period. Growth in the Biologics segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$146.0 Million While China is Forecast to Grow at 4.1% CAGR

The Vasculitis Treatment market in the U.S. is estimated at US$146.0 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$115.2 Million by the year 2030 trailing a CAGR of 4.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.1% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Vasculitis Treatment Market - Key Trends & Drivers Summarized

Why Is There an Increasing Focus on Vasculitis Treatment?

Vasculitis, a group of rare inflammatory diseases that cause blood vessel inflammation, has garnered increasing attention in the medical community due to its complex nature and potential for severe complications. The need for effective vasculitis treatment has grown as awareness of the disease and its varied presentations has increased. Early and accurate diagnosis is critical for managing vasculitis and preventing long-term damage to vital organs such as the kidneys, lungs, and heart. As healthcare providers and researchers work to develop more targeted and effective therapies, the demand for advanced treatment options has risen, driving growth in the vasculitis treatment market.

How Are Advances in Medicine Influencing Vasculitis Treatment?

Advances in medicine, particularly in immunology and biologic therapies, have significantly influenced the treatment of vasculitis. The development of targeted biologic drugs, such as rituximab and tocilizumab, which specifically modulate the immune response, has transformed the management of vasculitis, offering new hope to patients who do not respond to traditional therapies. Additionally, the use of advanced diagnostic tools, including imaging and molecular testing, has improved the ability to accurately diagnose and monitor vasculitis, leading to more personalized and effective treatment plans. The integration of these medical advancements into clinical practice has enhanced the ability to control disease activity, reduce relapses, and improve overall patient outcomes.

What Are the Emerging Trends in Vasculitis Treatment?

The vasculitis treatment market is witnessing several emerging trends that are shaping its development. One significant trend is the increasing use of biologic therapies, which offer a more targeted approach to treating vasculitis by modulating specific components of the immune system. Another trend is the growing focus on personalized medicine, with treatments tailored to the individual patient`s genetic and immunologic profile, leading to more effective and precise management of the disease. The market is also seeing a rise in the use of combination therapies, where biologics are used alongside traditional immunosuppressive drugs to achieve better control of disease activity. Additionally, there is an increasing emphasis on the development of novel therapeutic agents that can address unmet needs in vasculitis treatment, particularly for patients with refractory or severe disease.

What Factors Are Driving the Growth of the Vasculitis Treatment Market?

The growth in the vasculitis treatment market is driven by several factors, including the increasing prevalence and awareness of vasculitis, which has led to more frequent diagnoses and a greater need for effective treatments. The development of advanced biologic therapies, which have expanded the range of treatment options available to patients, is also a significant driver of market growth. Additionally, the growing emphasis on personalized medicine, driven by advances in genomics and molecular diagnostics, is influencing the adoption of more targeted therapies for vasculitis. The rising focus on improving patient outcomes, particularly in terms of reducing disease activity and preventing long-term complications, is further boosting demand for innovative treatment options. Moreover, the increasing investment in research and development, supported by government initiatives and collaborations between academic institutions and pharmaceutical companies, is contributing to the market`s expansion.

Select Competitors (Total 23 Featured) -
  • AB Science SA
  • Ablynx NV
  • Acorda Therapeutics, Inc.
  • Antares Pharma, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Can-Fite BioPharma Ltd.
  • Celgene Corporation
  • Celltrion Healthcare Co., Ltd.
  • Coherus BioSciences
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hospira, Inc.
  • Idera Pharmaceuticals, Inc.
  • Immunomedics, Inc.
  • Incyte Corporation
  • Lexicon Pharmaceuticals, Inc.
  • MedImmune LLC
  • Merck & Co., Inc.
  • Morphotek, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Regeneron Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Sanofi SA
  • Takeda Pharmaceutical Co., Ltd.
  • UCB SA
  • Vertex Pharmaceuticals Inc.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Vasculitis Treatment – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
Global Economic Update
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Prevalence of Autoimmune Disorders Driving Market Demand
Advancements in Biologic Therapies for Vasculitis
Increasing Adoption of Personalized Medicine in Vasculitis Treatment
Growing Demand for Immunosuppressive Drugs
Expansion of Clinical Trials for New Vasculitis Treatments
Technological Innovations in Diagnostic Tools for Vasculitis
Impact of Healthcare Reforms on Treatment Accessibility
Growing Awareness and Patient Education on Vasculitis
Emergence of Targeted Therapies for Specific Vasculitis Types
Increasing Investments in R&D for Vasculitis Therapeutics
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Vasculitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Vasculitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Vasculitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Immunosuppressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Immunosuppressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Immunosuppressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 13: World Vasculitis Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 14: USA Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 15: USA Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 16: USA 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
CANADA
TABLE 17: Canada Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 18: Canada Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 19: Canada 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
JAPAN
Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 20: Japan Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 21: Japan Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 22: Japan 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
CHINA
Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 23: China Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 24: China Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 25: China 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
EUROPE
Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 26: Europe Recent Past, Current & Future Analysis for Vasculitis Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 27: Europe Historic Review for Vasculitis Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 28: Europe 16-Year Perspective for Vasculitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 29: Europe Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 30: Europe Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 31: Europe 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
FRANCE
Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 32: France Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 33: France Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 34: France 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
GERMANY
Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 35: Germany Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 36: Germany Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 37: Germany 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
ITALY
TABLE 38: Italy Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 39: Italy Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 40: Italy 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
UNITED KINGDOM
Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 41: UK Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 42: UK Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 43: UK 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 45: Rest of Europe Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 46: Rest of Europe 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 48: Asia-Pacific Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 49: Asia-Pacific 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
REST OF WORLD
TABLE 50: Rest of World Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 51: Rest of World Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 52: Rest of World 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings